Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

AGILENT

Agilent provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling... read more Featured Products: More products

Download Mobile App




Cell-free RNA Profiles Gauge Preeclampsia Risk Months Before Symptoms

By LabMedica International staff writers
Posted on 18 Jan 2022
Print article
Image: The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries (Photo courtesy of Takara Bio)
Image: The SMARTer Stranded Total RNA-Seq Kit v2 - Pico Input Mammalian is used to generate strand-specific RNA-seq libraries (Photo courtesy of Takara Bio)
The period from conception to delivery represents the most rapid growth and development in an individual’s life. The ability to support this development requires dramatic and inadequately understood alterations in maternal physiology.

Preeclampsia, a pregnancy complication marked by the onset of hypertension, affects about 8% of pregnancies and contributes to maternal and neonatal morbidity and mortality. Signs of preeclampsia tend to arise late in pregnancy, and the disease is thought to originate with the establishment of the placenta in pregnancy.

A large team of clinical scientists including those at the Brigham and Women’s Hospital (Boston, MA, USA) and Mirvie, Inc., (South San Francisco, CA, USA) demonstrated the ability of plasma cell-free RNA (cfRNA) to reveal patterns of normal pregnancy progression and determine the risk of developing pre-eclampsia months before clinical presentation. The team gathered maternal transcriptome data from eight different prospective cohorts, pulling together data that encompassed 2,539 plasma samples and 1,840 pregnancies. This cohort included women of a range of ethnic, national, geographical, and socioeconomic backgrounds.

In particular, the scientists conducted a case-control study of 72 individuals with preeclampsia and 452 controls, including individuals with chronic hypertension and gestational hypertension using blood samples taken during the second trimester. They performed PCR with reverse transcription (RT–qPCR) analysis to assess the relative amount of cfRNA extracted from each sample. They measured and compared the threshold cycle (Ct) values from each RNA sample using a three-color multiplex qPCR assay. cfRNA libraries were prepared using the SMARTer Stranded Total RNAseq-Pico Input Mammalian kit (Takara Bio, Kusatsu, Japan). RNA measurements and fragment analysis was performed on a Fragment Analyzer 5300 (Agilent Technologies, San Diego, CA, USA).

The investigators identified seven genes whose signatures consistently separated cases and controls. Four of the genes, PAPPA2, CLDN7, TLE6, and FABP1, have functions linked to preeclampsia or to placental development and the three others, SNORD14A, PLEKHH1, and MAGEA10, have been tied bioinformatically to preeclampsia, though their functions are unclear.

At a sensitivity of 75%, a model based on these gene signatures had a positive predictive value of 32.3%, with a preeclampsia prevalence of 13.7% in the study. This, according to the team, is better than currently used clinical models, which have positive predictive values of 4.4%, and rely on maternal factors. The test also detected preeclampsia risk early in pregnancy. It correctly identified 73% of expectant mothers, who later had a medically indicated preterm birth three months before the onset of clinical symptoms or delivery.

The authors concluded that their findings can now be leveraged to more accurately provide information on future maternal and fetal health and disease. Thus, their approach opens new therapeutic windows to effectively decrease maternal and neonatal morbidity and mortality. The study was published on January 5, 2022 in the journal Nature.

Related Links:
Brigham and Women’s Hospital
Mirvie, Inc
Takara Bio
Agilent Technologies


Gold Member
Troponin T QC
Troponin T Quality Control
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Auto Clinical Chemistry Analyzer
cobas c 703
New
Total 25-Hydroxyvitamin D₂ & D₃ Assay
25-OH-VD Reagent Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The tiny clay-based materials can be customized for a range of medical applications (Photo courtesy of Angira Roy and Sam O’Keefe)

‘Brilliantly Luminous’ Nanoscale Chemical Tool to Improve Disease Detection

Thousands of commercially available glowing molecules known as fluorophores are commonly used in medical imaging, disease detection, biomarker tagging, and chemical analysis. They are also integral in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Pathology

view channel
Image: The ready-to-use DUB enzyme assay kits accelerate routine DUB activity assays without compromising data quality (Photo courtesy of Adobe Stock)

Sensitive and Specific DUB Enzyme Assay Kits Require Minimal Setup Without Substrate Preparation

Ubiquitination and deubiquitination are two important physiological processes in the ubiquitin-proteasome system, responsible for protein degradation in cells. Deubiquitinating (DUB) enzymes contain around... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.